Claim Missing Document
Check
Articles

Found 13 Documents
Search

Functional Food Processing Application as PMT (Providing Additional Food) for BADUTA in the Program to Support the Movement to Prevent Stunting in Medan Deli District Vivi Asfianti; Denny Satria; Ahmad Hafizullah Ritonga; Ahmad Fadli; Alfi Sapitri
GANDRUNG: Jurnal Pengabdian Kepada Masyarakat Vol. 5 No. 1 (2024): GANDRUNG: Jurnal Pengabdian Kepada Masyarakat
Publisher : Fakultas Olahraga dan Kesehatan, Universitas PGRI Banyuwangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36526/gandrung.v5i1.3216

Abstract

Stunting is a form of growth failure due to the accumulation of inadequate nutrition that lasts for a long time starting from pregnancy until the age of 24 months, characterized by body length or height being below standard, based on the PB/U or TB/U index, the results of these measurements are at the threshold < -2 SD, =-3 SD (short) and <-3 SD (very short). Based on WHO data (2020), the prevalence of stunting in children under five in the world is 149.2 million or around 22%, the national prevalence of stunting in 2022 is 21.6%, the prevalence of stunting in North Sumatra (January 2023) reaches 21.1%, ranked 17th from 34 provinces with the highest number of stunted children in Indonesia. The prevalence of stunting in Medan City (as of April 1 2023) is 298 children under five. Data obtained from the Medan Deli District Family Planning Coordinator, currently there are 28 stunted toddlers and 30 stunted toddlers, of the 28 stunted toddlers, 1 toddler has 'graduated' from stunting. The aim of this service is to apply functional food processing as PMT (Supplemental Food Provision) for BADUTA as an effort to support the Stunting Prevention Movement Program in accordance with PERPRES (2021) No. 72. In the outreach activities, pretest and posttest evaluation activities were carried out to determine the level of knowledge of participants regarding the provision of additional protein-rich functional food (PMT) in the form of cereal cookies to stunted toddlers and those at risk of stunting by providing simple choice questions that they had to answer. The results of the service obtained are functional stunting food products in the form of cookies containing porang flour and moringa
In Silico Evaluation of Cardiac Glycosides from Vernonia amygdalina as EGFR Inhibitors in Triple Negative Breast Cancer Gisela Agustin Habayahan; Denny Satria
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 27 No. 02 (2026): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol27-iss02/676

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies, emphasizing the urgent need for novel molecular inhibitors. Epidermal growth factor receptor (EGFR) is overexpressed in TNBC, but current inhibitors show limited clinical efficacy, indicating a significant therapeutic gap. This study aims to evaluate cardiac glycosides from Vernonia amygdalina as EGFR inhibitors using an integrated in silico approach. Docking results demonstrated that vernoniosides A3 exhibited the lowest binding energy of -12.2 kcal/mol, outperforming the native ligand (-9.0 kcal/mol) and gefitinib (-8.5 kcal/mol). Molecular dynamics (MD) simulations revealed that EGFR-vernoniosides A3 complex remained stable, with RMSD values within stable range (0.7-3.8 Å), RMSF values (0.4-8.3 Å), radius of gyration (Rg) (6.0-7.0 Å), solvent-accessible surface area (SASA) (830-871 Ų), while forming up to 15 hydrogen bonds. However, MM-PBSA analysis showed that binding free energy of vernoniosides A3 (321.60 ± 5084.43 kcal/mol) was lower than the native ligand (569.25 ± 8997.10 kcal/mol) and gefitinib (623.87 ± 9862.73 kcal/mol), indicating weaker thermodynamic binding strength. This discrepancy arises as docking measures potential binding in a static state, while MM-PBSA reflects dynamic, realistic binding strength. These results suggest that vernoniosides A3 shows promising binding affinity but requires further optimization and validation for TNBC therapy.
In Silico Evaluation of Bisbenzylisoquinoline Compounds from Stephania sp. as EGFR Inhibitors for Triple-Negative Breast Cancer Amanda, Amanda Triastuti; Denny Satria
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 27 No. 02 (2026): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol27-iss02/677

Abstract

Triple-negative breast cancer (TNBC) represents a highly aggressive breast malignancy subtype characterized by constrained therapeutic alternatives and poor clinical outcomes. Since Epidermal Growth Factor Receptor (EGFR) is frequently overexpressed in TNBC, it remains a strategic molecular target for anticancer drug innovation. This study evaluates the inhibitory potential of bisbenzylisoquinoline (BBIQ) compounds from Stephania species against EGFR using an in silico framework. Molecular docking analysis revealed that isotrilobine possessed the highest binding affinity toward EGFR, achieving a docking score of -10.5 kcal/mol, indicating potent interactions within the active site. Molecular dynamics simulations over a 100 ns trajectory demonstrated that the EGFR-isotrilobine complex maintained structural stability throughout, as evidenced by RMSD values of 0.193-1.223 Å, RMSF of 1.5 ± 1.1 Å, radius of gyration (Rg) of 4.597-4.918 Å, and a solvent-accessible surface area (SASA) of 772.3 Ų. Hydrogen bond analysis identified an average of four stable interactions, reinforcing persistent ligand binding within the receptor pocket. Furthermore, MM-PBSA calculations yielded a binding free energy of 101.063 ± 127.26 kJ/mol, indicating energetically favorable binding. These findings suggest that isotrilobine and related BBIQ analogues exhibit significant potential as EGFR inhibitors for TNBC therapy, serving as viable candidates for further experimental validation and drug development.